Legal & General Group
CSTL icon

Legal & General Group’s Castle Biosciences CSTL Stock Holding History

Legal & General Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Sell
20,548
-2,636
-11% -$58.7K ﹤0.01% 2404
2026
Q1 		$569K Sell
23,184
-6,551
-22% -$215K ﹤0.01% 2324
2025
Q4 		$1.16M Sell
29,735
-5,173
-15% -$167K ﹤0.01% 2175
2025
Q3 		$795K Hold
34,908
– – ﹤0.01% 2302
2025
Q2 		$713K Buy
34,908
+8,992
+35% +$166K ﹤0.01% 2335
2025
Q1 		$519K Sell
25,916
-36
-0.1% -$891 ﹤0.01% 2386
2024
Q4 		$692K Sell
25,952
-3,168
-11% -$96.5K ﹤0.01% 2352
2024
Q3 		$831K Buy
29,120
+4,730
+19% +$120K ﹤0.01% 2294
2024
Q2 		$531K Sell
24,390
-381
-2% -$8.49K ﹤0.01% 2404
2024
Q1 		$549K Sell
24,771
-50
-0.2% -$1.09K ﹤0.01% 2388
2023
Q4 		$536K Buy
24,821
+4,457
+22% +$78.4K ﹤0.01% 2420
2023
Q3 		$344K Sell
20,364
-245
-1% -$4.29K ﹤0.01% 2577
2023
Q2 		$283K Buy
20,609
+10,115
+96% +$205K ﹤0.01% 2650
2023
Q1 		$238K Buy
10,494
+674
+7% +$16.5K ﹤0.01% 2523
2022
Q4 		$231K Hold
9,820
– – ﹤0.01% 2552
2022
Q3 		$257K Buy
9,820
+707
+8% +$19.8K ﹤0.01% 2530
2022
Q2 		$200K Sell
9,113
-94
-1% -$2.18K ﹤0.01% 2635
2022
Q1 		$413K Buy
9,207
+223
+2% +$9.21K ﹤0.01% 2445
2021
Q4 		$385K Buy
8,984
+28
+0.3% +$1.46K ﹤0.01% 2494
2021
Q3 		$596K Buy
8,956
+3,894
+77% +$274K ﹤0.01% 2376
2021
Q2 		$372K Buy
5,062
+990
+24% +$65.4K ﹤0.01% 2394
2021
Q1 		$279K Buy
4,072
+2,162
+113% +$162K ﹤0.01% 2392
2020
Q4 		$128K Hold
1,910
– – ﹤0.01% 2520
2020
Q3 		$98K Buy
1,910
+219
+13% +$9.74K ﹤0.01% 2497
2020
Q2 		$64K Buy
1,691
+234
+16% +$8K ﹤0.01% 2653
2020
Q1 		$43K Buy
1,457
+768
+111% +$23.2K ﹤0.01% 2640
2019
Q4 		$24K Buy
689
+113
+20% +$2.76K ﹤0.01% 3129
2019
Q3 		$10K Buy
+576
New +$12.8K ﹤0.01% 3266

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legal & General Group's CSTL Position: Q2 2026 in Review

Legal & General Group reduced its Castle Biosciences (CSTL) stake by 11% in Q2 2026, selling an estimated $58.7K and leaving 20,548 shares worth $490K. The position accounts for ﹤0.01% of the portfolio, ranked #2404.

Legal & General Group first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.16M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Legal & General Group held 20,548 shares of Castle Biosciences worth $490K as of Q2 2026.
  • Legal & General Group sold 2,636 Castle Biosciences shares in Q2 2026, an estimated $58.7K.
  • Castle Biosciences made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2404 holding.
  • Legal & General Group first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • Legal & General Group's Castle Biosciences position peaked at $1.16M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.